We are a pre-clinical stage biotechnology company with a mission to treat solid tumors and arthritic disorders that depend on extracellular matrix (ECM) remodeling.

TEAM

Frederic Bard
​CEO & Scientific Founder​

Florian Schuster
​Investor & Advisor

Guy Heathers
CBO & Business Co-Founder

Kristina Rutkute
Director, Business Development

Cheng-I Wang
​Head of Antibody Development

Christopher Tan
Board Member